Citation: 李富宇, 程南生. 肝门部胆管癌的治疗现状与展望. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(7): 769-774. doi: 10.7507/1007-9424.201807002 Copy
1. | Dumitrascu T, Chirita D, Ionescu M, et al. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg, 2013, 17(5): 913-924. |
2. | Young AL, Igami T, Senda Y, Adair R, et al. Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxford), 2011, 13(7): 483-493. |
3. | Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg, 2001, 234(4): 507-519. |
4. | 董家鸿, 项灿宏. 肝门部胆管癌的精准外科手术治疗. 中华消化外科杂志, 2013, 12(3): 170-173. |
5. | Saxena A, Chua TC, Chu FC, et al. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg, 2011, 202(3): 310-320. |
6. | 中华医学会外科学分会胆道外科学组, 解放军全军肝胆外科专业委员会. 肝门部胆管癌诊断和治疗指南(2013版). 中华外科杂志, 2013, 51(10): 865-871. |
7. | Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg, 2014, 399(6): 693-705. |
8. | Liu CL, Fan ST, Lo CM, et al. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg, 2006, 93(12): 1488-1494. |
9. | Witzigmann H, Berr F, Ringel U, Caca K, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg, 2006, 244(2): 230-239. |
10. | Golfieri R, Giampalma E, Renzulli M, et al. Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo, 2006, 20(6A): 757-760. |
11. | Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol, 2005, 14(2): 59-74. |
12. | Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg, 2007, 31(6): 1256-1263. |
13. | Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg, 2008, 248(2): 273-279. |
14. | Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center’s experience. Am J Surg, 2008, 196(2): 160-169. |
15. | Robles R, Figueras J, Turrión VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg, 2004, 239(2): 265-271. |
16. | Ramacciato G, Nigri G, Bellagamba R, et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg, 2010, 76(11): 1260-1268. |
17. | Hemming AW, Mekeel K, Khanna A, et al. Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg, 2011, 212(4): 604-616. |
18. | Wang JK, Hu HJ, Shrestha A, et al. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget, 2017, 8(28): 45335-45344. |
19. | Hu HJ, Mao H, Tan YQ, et al. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus, 2016, 5: 551. |
20. | Hu HJ, Shrestha A, Mao H, et al. Impact of different tumor size cut-off points on survival outcome after curative resection of hilar cholangiocarcinoma. Int J Clin Exp Med, 2016, 9: 6178-6189. |
21. | Hu HJ, Zhou RX, Shrestha A, et al. Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma. Oncotarget, 2017, 8(62): 105011-105019. |
22. | Dinant S, Gerhards MF, Rauws EA, et al. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol, 2006, 13(6): 872-880. |
23. | Tsuchikawa T, Hirano S, Okamura K, et al. Advances in the surgical treatment of hilar cholangiocarcinoma. Expert Rev Gastroenterol Hepatol, 2015, 9(3): 369-374. |
24. | 鲁正, 王冬冬. Bismuth-Corlette Ⅲ、Ⅳ型肝门部胆管癌的手术治疗方式. 中华外科杂志, 2016, 54(7): 488-491. |
25. | Conci S, Ruzzenente A, Sandri M, et al. What is the most accurate lymph node staging method for perihilar cholangiocarcinoma? Comparison of UICC/AJCC pN stage, number of metastatic lymph nodes, lymph node ratio, and log odds of metastatic lymph nodes. Eur J Surg Oncol, 2017, 43(4): 743-750. |
26. | Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392. |
27. | Bagante F, Tran T, Spolverato G, et al. Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme. J Am Coll Surg, 2016, 222(5): 750-759.e2. |
28. | Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. New York: Springer, 2017. |
29. | National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hepatobiliary Cancers, V.1.2018. Available at http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. |
30. | Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3rd English edition. J Hepato Biliary Pancreat Sci, 2015, 22(3): 181-196. |
31. | Murakami Y, Uemura K, Sudo T, et al. Is para-aortic lymph node metastasis a contraindication for radical resection in biliary carcinoma? World J Surg, 2011, 35(5): 1085-1093. |
32. | Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol, 2016, 22(8): 2601-2610. |
33. | 张辉, 王孟龙. 肝门部胆管癌的可切除性评估. 中华肝胆外科杂志, 2015, 21(11): 789-792. |
34. | Zaydfudim VM, Rosen CB, Nagorney DM. Hilar cholangiocarcinoma. Surg Oncol Clin N Am, 2014, 23(2): 247-263. |
35. | Ito F, Cho CS, Rikkers LF, et al. Hilar cholangiocarcinoma: current management. Ann Surg, 2009, 250(2): 210-218. |
36. | Kow AW, Wook CD, Song SC, et al. Role of caudate lobectomy in type ⅢA and ⅢB hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg, 2012, 36(5): 1112-1121. |
37. | Cheng QB, Yi B, Wang JH, et al. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type Ⅲ and Ⅳ. Eur J Surg Oncol, 2012, 38(12): 1197-1203. |
38. | Chen W, Ke K, Chen YL. Combined portal vein resection in the treatment of hilar cholangiocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol, 2014, 40(5): 489-495. |
39. | Miyazaki M, Kato A, Ito H, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery, 2007, 141(5): 581-588. |
40. | Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg, 2010, 252(1): 115-123. |
41. | Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg, 2003, 238(5): 720-727. |
42. | Wu XS, Dong P, Gu J, et al. Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies. J Gastrointest Surg, 2013, 17(6): 1107-1115. |
43. | 倪其泓, 王坚. 肝门部胆管癌诊断和治疗指南(2013版)的解读与思考. 肝胆胰外科杂志, 2015, 27(6): 450-454. |
44. | Govil S, Reddy MS, Rela M. Surgical resection techniques for locally advanced hilar cholangiocarcinoma. Langenbecks Arch Surg, 2014, 399(6): 707-716. |
45. | Schimizzi GV, Jin LX, Davidson JT 4th, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford), 2018, 20(4): 332-339. |
46. | Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford), 2013, 15(7): 492-503. |
47. | Yu W, Gu Z, Shi S et al. Yu W, Gu Z, Shi S, et al. Effect evaluation of vascular resection for patients with hilar cholangiocarcinoma: original data and meta-analysis. Cell Biochem Biophys, 2014, 69(3): 509-516. |
48. | Peng C, Li C, Wen T, et al. Left hepatectomy combined with hepatic artery resection for hilar cholangiocarcinoma: A retrospective cohort study. Int J Surg, 2016, 32: 167-173. |
49. | Hu HJ, Jin YW, Zhou RX, et al. Hepatic artery resection for Bismuth type Ⅲ and Ⅳ hilar cholangiocarcinoma: is reconstruction always required?. J Gastrointest Surg, 2018, Mar 6. doi: 10.1007/s11605-018-3711-3. |
50. | Alessiani M, Tzakis A, Todo S, et al. Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg, 1995, 180(1): 1-9. |
51. | 李文杰, 梁雨荣. 肝门部胆管癌的诊疗现状. 中华肝胆外科杂志, 2015, 21(4): 281-283. |
52. | Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc, 2009, 41(10): 4023-4035. |
53. | Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg, 2005, 242(3): 451-461. |
54. | Gores GJ. Liver transplantation for cholangiocarcinoma. Liver Transpl, 2015, 21 Suppl 1: S32-S33. |
55. | Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation, 2006, 82(12): 1703-1707. |
56. | Soares KC, Kamel I, Cosgrove DP, et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr, 2014, 3(1): 18-34. |
57. | Valero V 3rd, Cosgrove D, Herman JM, et al. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol, 2012, 6(4): 481-495. |
58. | Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer, 2010, 103(4): 469-474. |
59. | Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010, 362(14): 1273-1281. |
60. | Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg, 2009, 13(8): 1470-1479. |
61. | Bridgewater JA, Stubbs C, Primrose JN. BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. J Clin Oncol, 2011, 29(15): 2696. |
62. | Glazer ES, Liu P, Abdalla EK, et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg, 2012, 16(9): 1666-1671. |
63. | Howell M, Valle JW. The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. Best Pract Res Clin Gastroenterol, 2015, 29(2): 333-343. |
64. | 萧嘉铭, 董高宏. 肝门部胆管癌的治疗现状. 中国肿瘤外科杂志, 2015, 7(6): 390-393. |
65. | 闫炫炫, 李多富, 李汛. 光动力疗法在不可切除肝门部胆管癌中的应用. 中国普外基础与临床杂志, 2018, 25(4): 488-492. |
66. | Ortner ME, Caca K, Berr F,et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology, 2003, 125(5): 1355-163. |
67. | Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11): 2426-2430. |
68. | Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase Ⅱ pilot study. Cancer, 2003, 97(11): 2783-2790. |
- 1. Dumitrascu T, Chirita D, Ionescu M, et al. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg, 2013, 17(5): 913-924.
- 2. Young AL, Igami T, Senda Y, Adair R, et al. Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxford), 2011, 13(7): 483-493.
- 3. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg, 2001, 234(4): 507-519.
- 4. 董家鸿, 项灿宏. 肝门部胆管癌的精准外科手术治疗. 中华消化外科杂志, 2013, 12(3): 170-173.
- 5. Saxena A, Chua TC, Chu FC, et al. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg, 2011, 202(3): 310-320.
- 6. 中华医学会外科学分会胆道外科学组, 解放军全军肝胆外科专业委员会. 肝门部胆管癌诊断和治疗指南(2013版). 中华外科杂志, 2013, 51(10): 865-871.
- 7. Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg, 2014, 399(6): 693-705.
- 8. Liu CL, Fan ST, Lo CM, et al. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg, 2006, 93(12): 1488-1494.
- 9. Witzigmann H, Berr F, Ringel U, Caca K, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg, 2006, 244(2): 230-239.
- 10. Golfieri R, Giampalma E, Renzulli M, et al. Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo, 2006, 20(6A): 757-760.
- 11. Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol, 2005, 14(2): 59-74.
- 12. Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg, 2007, 31(6): 1256-1263.
- 13. Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg, 2008, 248(2): 273-279.
- 14. Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center’s experience. Am J Surg, 2008, 196(2): 160-169.
- 15. Robles R, Figueras J, Turrión VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg, 2004, 239(2): 265-271.
- 16. Ramacciato G, Nigri G, Bellagamba R, et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg, 2010, 76(11): 1260-1268.
- 17. Hemming AW, Mekeel K, Khanna A, et al. Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg, 2011, 212(4): 604-616.
- 18. Wang JK, Hu HJ, Shrestha A, et al. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget, 2017, 8(28): 45335-45344.
- 19. Hu HJ, Mao H, Tan YQ, et al. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus, 2016, 5: 551.
- 20. Hu HJ, Shrestha A, Mao H, et al. Impact of different tumor size cut-off points on survival outcome after curative resection of hilar cholangiocarcinoma. Int J Clin Exp Med, 2016, 9: 6178-6189.
- 21. Hu HJ, Zhou RX, Shrestha A, et al. Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma. Oncotarget, 2017, 8(62): 105011-105019.
- 22. Dinant S, Gerhards MF, Rauws EA, et al. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol, 2006, 13(6): 872-880.
- 23. Tsuchikawa T, Hirano S, Okamura K, et al. Advances in the surgical treatment of hilar cholangiocarcinoma. Expert Rev Gastroenterol Hepatol, 2015, 9(3): 369-374.
- 24. 鲁正, 王冬冬. Bismuth-Corlette Ⅲ、Ⅳ型肝门部胆管癌的手术治疗方式. 中华外科杂志, 2016, 54(7): 488-491.
- 25. Conci S, Ruzzenente A, Sandri M, et al. What is the most accurate lymph node staging method for perihilar cholangiocarcinoma? Comparison of UICC/AJCC pN stage, number of metastatic lymph nodes, lymph node ratio, and log odds of metastatic lymph nodes. Eur J Surg Oncol, 2017, 43(4): 743-750.
- 26. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392.
- 27. Bagante F, Tran T, Spolverato G, et al. Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme. J Am Coll Surg, 2016, 222(5): 750-759.e2.
- 28. Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. New York: Springer, 2017.
- 29. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hepatobiliary Cancers, V.1.2018. Available at http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
- 30. Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3rd English edition. J Hepato Biliary Pancreat Sci, 2015, 22(3): 181-196.
- 31. Murakami Y, Uemura K, Sudo T, et al. Is para-aortic lymph node metastasis a contraindication for radical resection in biliary carcinoma? World J Surg, 2011, 35(5): 1085-1093.
- 32. Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol, 2016, 22(8): 2601-2610.
- 33. 张辉, 王孟龙. 肝门部胆管癌的可切除性评估. 中华肝胆外科杂志, 2015, 21(11): 789-792.
- 34. Zaydfudim VM, Rosen CB, Nagorney DM. Hilar cholangiocarcinoma. Surg Oncol Clin N Am, 2014, 23(2): 247-263.
- 35. Ito F, Cho CS, Rikkers LF, et al. Hilar cholangiocarcinoma: current management. Ann Surg, 2009, 250(2): 210-218.
- 36. Kow AW, Wook CD, Song SC, et al. Role of caudate lobectomy in type ⅢA and ⅢB hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg, 2012, 36(5): 1112-1121.
- 37. Cheng QB, Yi B, Wang JH, et al. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type Ⅲ and Ⅳ. Eur J Surg Oncol, 2012, 38(12): 1197-1203.
- 38. Chen W, Ke K, Chen YL. Combined portal vein resection in the treatment of hilar cholangiocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol, 2014, 40(5): 489-495.
- 39. Miyazaki M, Kato A, Ito H, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery, 2007, 141(5): 581-588.
- 40. Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg, 2010, 252(1): 115-123.
- 41. Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg, 2003, 238(5): 720-727.
- 42. Wu XS, Dong P, Gu J, et al. Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies. J Gastrointest Surg, 2013, 17(6): 1107-1115.
- 43. 倪其泓, 王坚. 肝门部胆管癌诊断和治疗指南(2013版)的解读与思考. 肝胆胰外科杂志, 2015, 27(6): 450-454.
- 44. Govil S, Reddy MS, Rela M. Surgical resection techniques for locally advanced hilar cholangiocarcinoma. Langenbecks Arch Surg, 2014, 399(6): 707-716.
- 45. Schimizzi GV, Jin LX, Davidson JT 4th, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford), 2018, 20(4): 332-339.
- 46. Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford), 2013, 15(7): 492-503.
- 47. Yu W, Gu Z, Shi S et al. Yu W, Gu Z, Shi S, et al. Effect evaluation of vascular resection for patients with hilar cholangiocarcinoma: original data and meta-analysis. Cell Biochem Biophys, 2014, 69(3): 509-516.
- 48. Peng C, Li C, Wen T, et al. Left hepatectomy combined with hepatic artery resection for hilar cholangiocarcinoma: A retrospective cohort study. Int J Surg, 2016, 32: 167-173.
- 49. Hu HJ, Jin YW, Zhou RX, et al. Hepatic artery resection for Bismuth type Ⅲ and Ⅳ hilar cholangiocarcinoma: is reconstruction always required?. J Gastrointest Surg, 2018, Mar 6. doi: 10.1007/s11605-018-3711-3.
- 50. Alessiani M, Tzakis A, Todo S, et al. Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg, 1995, 180(1): 1-9.
- 51. 李文杰, 梁雨荣. 肝门部胆管癌的诊疗现状. 中华肝胆外科杂志, 2015, 21(4): 281-283.
- 52. Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc, 2009, 41(10): 4023-4035.
- 53. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg, 2005, 242(3): 451-461.
- 54. Gores GJ. Liver transplantation for cholangiocarcinoma. Liver Transpl, 2015, 21 Suppl 1: S32-S33.
- 55. Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation, 2006, 82(12): 1703-1707.
- 56. Soares KC, Kamel I, Cosgrove DP, et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr, 2014, 3(1): 18-34.
- 57. Valero V 3rd, Cosgrove D, Herman JM, et al. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol, 2012, 6(4): 481-495.
- 58. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer, 2010, 103(4): 469-474.
- 59. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010, 362(14): 1273-1281.
- 60. Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg, 2009, 13(8): 1470-1479.
- 61. Bridgewater JA, Stubbs C, Primrose JN. BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. J Clin Oncol, 2011, 29(15): 2696.
- 62. Glazer ES, Liu P, Abdalla EK, et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg, 2012, 16(9): 1666-1671.
- 63. Howell M, Valle JW. The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. Best Pract Res Clin Gastroenterol, 2015, 29(2): 333-343.
- 64. 萧嘉铭, 董高宏. 肝门部胆管癌的治疗现状. 中国肿瘤外科杂志, 2015, 7(6): 390-393.
- 65. 闫炫炫, 李多富, 李汛. 光动力疗法在不可切除肝门部胆管癌中的应用. 中国普外基础与临床杂志, 2018, 25(4): 488-492.
- 66. Ortner ME, Caca K, Berr F,et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology, 2003, 125(5): 1355-163.
- 67. Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11): 2426-2430.
- 68. Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase Ⅱ pilot study. Cancer, 2003, 97(11): 2783-2790.
-
Previous Article
颈内静脉大隐静脉转流术在上腔静脉破裂中的应用一例 -
Next Article
肝门部胆管癌根治术区域淋巴结清扫范围探讨